drugset / Trial / NCT07692178

An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers

NCT07692178 ↗

Phase 2 Not yet recruiting 20 enrolled MediWound Ltd TFS Health Science · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a pharmacokinetics (PK) study - the main objective of this study is to assess the PK, safety and clinical performance of 5% EscharEx (EX-03 formulation) in debridement of Venous Leg Ulcers

Timeline

Start
2026-08
Primary completion
2028-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator anacaulase-bcdb Protein / enzyme biologic 5 % —

Indications